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Abstract
Background: In 2006, the Bowel Cancer Screening Programme (BCSP) in England began
offering biennial faecal occult blood testing (FOBt) at ages 60–69 years. Although FOBt is
aimed at detecting colorectal neoplasms, other conditions can affect the result. In a large
UK prospective study, we examined associations, both before and after screening, between
FOBt positivity and 10 conditions that are often associated with gastrointestinal bleeding.
Methods: By electronically linking BCSP and Million Women Study records, we identified
604 495 women without previous colorectal cancer who participated in their first routine
FOBt screening between 2006 and 2012. Regression models, using linked national
hospital admission records, yielded adjusted relative risks (RRs) in FOBt-positive versus
FOBt-negative women for colorectal cancer, adenoma, diverticular disease, inflamma-
tory bowel disease, haemorrhoids, upper gastrointestinal cancer, oesophagitis, peptic ul-
cer, anaemia and other haematological disorders.
Findings: RRs in FOBt-positive versus FOBt-negative women were 201.3 (95% CI 173.8–233.2)
for colorectal cancer and 197.9 (95% CI 180.6–216.8) for adenoma within 12months after
screening and 3.49 (95% CI 2.31–5.26) and 4.88 (95% CI 3.80–6.26), respectively, 12–24months
after screening; P< 0.001 for all RRs. In the 12 months after screening, the RR for inflammatory
bowel disease was 26.3 (95% CI 19.9–34.7), and ranged between 2 and 5 for the upper gastroin-
testinal or haematological disorders. The RRs of being diagnosed with any of the eight
conditions other than colorectal neoplasms before screening, and in the 12–24months after
screening, were 1.81 (95% CI 1.81–2.01) and 1.92 (95% CI 1.66–2.13), respectively.
VC The Author(s) 2019. Published by Oxford University Press on behalf of the International Epidemiological Association. 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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Conclusions: Whereas FOBt positivity is associated with a substantially increased risk of
colorectal neoplasms after screening, eight other gastrointestinal and haematological
conditions are also associated with FOBt positivity, both before and after screening.
Key words: Bowel cancer screening, faecal occult blood test, bowel cancer, colonoscopy, upper gastrointestinal
bleeding
Background
Colorectal cancer is the third most common cause of can-
cer deaths in the UK, and accounted for 12% of all new
cancers in 2014.1 As colorectal cancers are prone to bleed-
ing, the rationale for screening with faecal occult blood
test (FOBt) is to detect blood originating from otherwise
asymptomatic tumours, thereby enabling diagnosis at an
early, potentially curable stage.2–5 Although it is acknowl-
edged that FOBt positivity can be affected by a range of
conditions other than colorectal cancer,6 no previous study
has evaluated the associations of FOBt positivity with
other gastrointestinal or haematological conditions in a
population-based bowel cancer screening programme.
Quantifying associations between FOBt positivity and
colorectal cancer, as well as other gastrointestinal and hae-
matological conditions, may help guide clinical decision
making at both a population and an individual level.
The National Health Service (NHS) Bowel Cancer
Screening Programme (BCSP) in England was launched
in 2006 to provide biennial colorectal cancer screening
using guaiac-based FOBt. In this report, we link FOBt
results in the BCSP with information on cause-specific
hospital admissions in the large prospective study of
women’s health, the Million Women Study. We investi-
gated associations between FOBt positivity and 10 pre-
specified conditions related to gastrointestinal bleeding.
Methods
The Bowel Cancer Screening Programme in
England
The BCSP in England began offering biennial screening with
FOBt to men and women aged 60–69 years from 2006 (ex-
tended to 74 years from 2010).7,8 Those defined as FOBt-
positive by the BCSP were referred to specialist screening
nurses at bowel cancer screening centres for further investi-
gations. In most cases, this investigation was a colonoscopy;
radiological imaging was performed in the small minority
deemed unsuitable for colonoscopy. The BCSP records indi-
vidual data, including the dates of screening invitations,
FOBt results and, for those who were FOBt-positive, find-
ings of further investigations organized by the BCSP.
The Million Women Study
The Million Women Study is a large nationwide study of
women’s health. A total of 1.3 million women, represent-
ing one in four of all UK women born in 1935–50, joined
the study in 1996–2001. Participants answered a question-
naire on sociodemographic, health and lifestyle character-
istics, and consented to follow-up through medical
records. Details of the study design have been published
elsewhere.9,10 Questionnaires and information on data
Key Messages
• In the first 12 months after screening, women who are FOBt-positive have about a 200-fold increase in the risk of co-
lorectal neoplasia. This excess risk remains slightly elevated in the 12–24 months after screening.
• FOBt positivity is associated with an increased risk of being diagnosed with non-neoplastic colorectal conditions that
can also cause gastrointestinal bleeding. The greatest relative risk, both before and after FOBt positivity, is for inflam-
matory bowel disease.
• Bleeding from upper gastrointestinal conditions, especially peptic ulcers, makes a sizeable contribution to FOBt positiv-
ity. However, the proportion of FOBt-positive women subsequently diagnosed with upper gastrointestinal cancer is ex-
ceedingly low.
• About one in eight women who were FOBt-positive did not undertake follow-up investigations through services pro-
vided by the national Bowel Cancer Screening Programme, but many of them had pre-existing conditions associated
with gastrointestinal bleeding and appear to have chosen to seek follow-up through other services where they were
already under the care.
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access for the study can be viewed at www.millionwo
menstudy.org.
Using their unique NHS number and other identifying
details, study participants are followed by linkage to elec-
tronic, routinely collected NHS records for deaths, cancer
registrations and hospital admissions. Data for England
are provided through NHS Digital. The Hospital Episode
Statistics (HES) inpatient dataset in England contains
details of all NHS inpatient (overnight and day case)
admissions, including private patients treated in NHS hos-
pitals. Diagnoses are recorded using the Tenth Revision of
the International Classification of Diseases (ICD-10).11
Colonoscopies are generally performed as ‘day cases’ in
NHS hospitals, and their findings are recorded in the
HES database. Cancer registration, death and emigration
records are available from recruitment to 31 December
2014 and HES records from 1 April 1997 to 31 December
2014.
With approval from the Cambridge South Research
Ethics Committee and by the NHS Bowel Cancer
Screening Programme Research Committee, the BCSP
database was linked to the Million Women Study database
in 2013 (done by NHS Connecting for Health, now NHS
Digital).
Outcomes
Linked HES records were searched for hospital admission
with diagnoses of the following 10 pre-specified
gastrointestinal and haematological conditions: colorectal
cancer, colorectal adenoma, inflammatory bowel disease,
diverticular disease, haemorrhoids, peptic ulcer disease,
oesophagitis, upper gastrointestinal cancer, anaemia and
other bleeding disorders. Table 1 gives the ICD-10 codes
used to define each of the 10 conditions. More than one di-
agnosis may have been recorded in a single hospital admis-
sion. We did validation analyses for colorectal cancer using
cases ascertained from the cancer registry data.8
Conditions were defined as being diagnosed ‘before
screening’ if the first hospital record for the condition was
before the first BCSP screening invitation. Conditions were
defined as being diagnosed ‘after screening’ if the first hos-
pital record of the condition was after the first screening
invitation. First diagnoses after screening were further
divided into those in the first 12 months after screening in-
vitation (i.e. including results of diagnostic investigations
following a positive screening test) and those first recorded
in the 12–24 months after screening. Diagnoses after
24 months were not included, as the BCSP would have of-
fered many women routine screening again 24 months after
Table 1. Classification of HES diagnoses using ICD-10
Diagnosis in analysis ICD-10a Description
Colorectal cancer C18 Malignant neoplasm of colon
C19 Malignant neoplasm of rectosigmoid junction
C20 Malignant neoplasm of rectum
Colorectal adenoma D12 Benign neoplasm of colon, rectum, anus or anal canal
Inflammatory bowel disease K50 Crohn’s disease [regional enteritis]
K51 Ulcerative colitis
Diverticular disease K57 Diverticular disease of intestine
Haemorrhoids I84 Haemorrhoids
Peptic ulcer disease K25 Gastric ulcer
K26 Duodenal ulcer
K27 Peptic ulcer, site unspecified
K28 Gastrojejunal ulcer
K29 Gastritis and duodenitis
Oesophagitis K20 Oesophagitis
K21 Gastro-oesophageal reflux disease
Upper gastrointestinal cancer C15 Malignant neoplasm of oesophagus
C16 Malignant neoplasm of stomach
C17 Malignant neoplasm of small intestine
Anaemias D50 Iron deficiency anaemia
D51 Vitamin B12 deficiency anaemia
D52 Folate deficiency anaemia
D53 Other nutritional anaemias
Haematological conditions D65-D69 Coagulation defects, purpura and other haemorrhagic conditions
D70-D77 Other diseases of blood and blood-forming organs
C81-C96 Malignant neoplasm of lymphoid, haematopoietic and related tissue
aFirst three characters of ICD-10 codes were used to define diagnoses used in the analysis.
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the first invitation. For FOBt-positive patients who under-
went subsequent colonoscopy, the information was
obtained from hospital diagnoses in the HES database, as
colonoscopies are generally performed as inpatient ‘day
cases’ in NHS hospitals.
Statistical analysis
Record linkage identified 899 166 Million Women Study
participants who received their first invitation for routine
bowel cancer screening from the BCSP (prevalent screening
round). For these analyses, we excluded women who did
not accept the invitation for screening (n¼ 278 705), had
any solid or haematological malignancy registered before
recruitment into Million Women Study (n¼ 15 144), were
lost to follow-up before first BCSP invitation (n¼ 22) or
had a hospital record of colorectal cancer before FOBt
screening (n¼ 800). The remaining 604 495 participants,
first screened for bowel cancer between 2006 and 2012,
were included in the analyses.
For conditions first diagnosed before screening, logistic
regression models estimated odds ratios, henceforth re-
ferred to as relative risks (RRs), for various diagnoses in
FOBt-positive versus FOBt-negative women. For condi-
tions first diagnosed after screening, Cox regression mod-
els, with attained age as the underlying time variable,
estimated hazard ratios, henceforth also referred to as rela-
tive risks (RRs), for first hospital diagnoses in FOBt-
positive versus FOBt-negative women in the first
12 months after screening, and 12–24 months after screen-
ing. For every RR estimate, 95% confidence intervals (CI)
were calculated.
All analyses were adjusted for area deprivation (based
on the Townsend index12), smoking (never, past, current),
alcohol consumption in drinkers (<2, 3–14, 15 drinks
per week) and body mass index (<25, 25–29, 30þ kg/m2),
as these have been associated increased risk of colorectal
cancer. Information relating to these variables was
obtained at recruitment; women with missing data on ad-
justment variables (<2% for each) were included in the
analyses as a separate category. Information on family his-
tory of colorectal cancer and use of antiplatelet or antico-
agulant medications were not collected at recruitment.
Analyses of diagnoses other than colorectal neoplasms
(cancer or adenoma) excluded women with colorectal can-
cer diagnosed in the 24 months after screening. All analyses
were performed using Stata version 14.0.
Results
Of the 604 495 women without previous colorectal
cancer who had a routine FOBt screen, 8852 (1.5%) were
FOBt-positive and referred for further investigations in the
Bowel Cancer Screening Programme (BCSP). All FOBt
screening was performed between 13 July 2006 and 13
March 2012.
The baseline characteristics and the frequency of condi-
tions recorded in hospital admission data before the FOBt
screen are shown in Table 2. Results are given for nine of
the 10 gastrointestinal and haematological conditions be-
ing investigated here, as the 10th condition is colorectal
cancer, and women with previous colorectal cancer were
excluded from these analyses.
Before screening, FOBt-positive women were more likely
than FOBt-negative women to have had previous diagnoses
of colorectal adenoma or non-neoplastic colorectal condi-
tions (inflammatory bowel disease, diverticular disease and
haemorrhoids), as well as upper gastrointestinal conditions
(oesophagitis, peptic ulcer disease and upper gastrointestinal
cancer). FOBt-positive women were also more likely than
FOBt-negative women to have had a previous admission for
anaemia or other haematological disorders. The proportions
of women admitted with at least one of the eight conditions
(other than colorectal adenoma) before FOB testing were
25% of FOBt-positive and 16% of FOBt-negative partici-
pants. The pre-screening diagnoses most strongly associated
with FOBt positivity were inflammatory bowel disease
(RR¼6.06, 5.11 – 7.18; P<0.0001) and anaemia
(RR¼4.20, 3.74 – 4.71; P<0.0001).
Of the FOBt-positive women, 7687 (87%) attended the
BCSP for further investigations, which for almost all
women was a colonoscopy. Among the 1174 (13%) FOBt-
positive women who did not attend the BCSP for further
investigation, hospital admission records indicate that they
were significantly more likely than the attenders to have
had previous hospital admissions for each of the nine pre-
selected gastrointestinal and haematological conditions,
particularly inflammatory bowel disease and anaemia
(Table 3).
In all, 700 (7.9%) FOBt-positive women had a hospital
diagnosis for colorectal cancer and 1704 (19%) for colo-
rectal adenoma in the first 12 months after screening.
Among the FOBt-negative women, the corresponding
numbers were 247 and 649, yielding relative risks of
201.3 (173.8 – 233.2) and 197.9 (180.6 – 216.8) for colo-
rectal cancer and for adenoma in FOBt-positive compared
with FOBt-negative women. Results for colorectal cancer
were similar, based on cancers ascertained from the cancer
registry data, at 212.0 (184.0 – 246.5).
In the first 12 months after screening, FOBt positivity
was also associated with large increases in non-neoplastic
colorectal conditions, with 1717 FOBt-positive women di-
agnosed with diverticular disease (RR¼42.0, 39.6 – 44.6),
612 with haemorrhoids (RR¼ 28.5, 25.9 – 31.3) and 70
4 International Journal of Epidemiology, 2019, Vol. 0, No. 0
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with inflammatory bowel disease (RR¼26.3, 19.9 – 34.7);
P<0.0001 for all the RRs quoted (Figure 1A). Virtually all
the colorectal conditions (both neoplastic and non-
neoplastic) were recorded in the 6 months after the FOBt
screening invitation and were probably diagnosed as a re-
sult of the BCSP referral.
After excluding those diagnosed with colorectal cancer
after screening, FOBt positivity was associated with a
Table 2. Baseline characteristics and pre-screening HES diagnoses for hospital admissions in FOBt-positive women (n¼8852)
versus FOBt-negative women (n¼ 595 643)
Participant characteristics FOBt-positive (n¼8 852), % (n) FOBt-negative (n¼595 643), % (n)
Mean age at first invitation to bowel screening, years (SD) 65.9 (3.7) 65.3 (3.6)
Socioeconomic group (% in upper third) 31.2% (2757) 36.0% (14 377)
Current smoker 18.0% (1596) 15.8% (93 980)
Body mass index 30 kg m2 23.7% (2100) 15.1% (89 618)
Alcohol intake 30 g per week 41.3% (3655) 43.5% (258 826)
Hospital admission before routine FOB testing for nine pre-specified conditionsa
Colorectal neoplasms
Colorectal adenomas 1.97% (174) 0.93% (5562)
Colorectal non-neoplastic
Inflammatory bowel disease 1.79% (146) 0.27% (1614)
Diverticular disease 6.27% (511) 3.19% (18 975)
Haemorrhoids 5.12% (417) 2.54% (15 131)
Upper gastrointestinal
Oesophagitis 6.99% (570) 4.37% (26 009)
Peptic ulcer 9.29% (757) 5.24% (31 177)
Upper gastrointestinal cancer 0.15% (12) 0.06% (332)
Haematological
Anaemia 3.86% (315) 0.82% (4867)
Potential bleeding tendency 6.43% (524) 2.16% (12 880)
Any of the above conditions, except colorectal neoplasms 25.2% (2007) 15.6% (82 677)
aWomen with the 10th condition being investigated, colorectal cancer, were excluded from these analyses if the cancer had been diagnosed before routine
screening.
Table 3. Pre-screening diagnoses in FOBt-positive womena by attendance at Bowel Cancer Screening Programme for further
diagnostic tests
FOBt-positive who attended BCSP
for further diagnostic tests (n¼7678)
FOBt-positive who did not attend BCSP
for further diagnostic tests (n¼1174)
% (n) Adjusted RRb (95% CI) % (n) Adjusted RRb (95% CI)
Colorectal neoplasms
Colorectal adenoma 1.52% (117) 1.49 (1.24 – 1.79) 4.86% (57) 4.62 (3.53 – 6.04)
Colorectal non-neoplastic
Inflammatory bowel disease 0.82% (63) 2.93 (2.28 – 3.78) 7.33% (86) 27.2 (21.66 – 34.08)
Diverticular disease 5.25% (403) 1.48 (1.34 – 1.64) 10.2% (120) 2.92 (2.41 – 3.53)
Haemorrhoids 4.39% (337) 1.68 (1.51 – 1.88) 7.92% (93) 3.10 (2.5 – 3.83)
Upper gastrointestinal
Oesophagitis 6.90% (530) 1.48 (1.35 – 1.62) 7.16% (84) 1.48 (1.19 – 1.85)
Peptic ulcer disease 8.44% (648) 1.53 (1.41 – 1.66) 12.0% (141) 2.15 (1.8 – 2.56)
Upper gastrointestinal cancer 0.13% (10) 2.17 (1.15 – 4.07) 0.17% (2) 2.70 (0.67 – 10.88)
Haematological
Anaemia 2.90% (223) 3.34 (2.92 – 3.83) 8.43% (99) 9.97 (8.09 – 12.3)
Potential bleeding tendency 4.98% (382) 2.19 (1.97 – 2.43) 13.3% (156) 6.20 (5.22 – 7.35)
Any of the above, except colorectal neoplasms 22.2% (1681) 1.62 (1.53 – 1.71) 38.0% (424) 3.39 (3.00 – 3.83)
aWomen with the 10th condition being investigated, colorectal cancer, were excluded from these analyses if the cancer had been diagnosed prior to routine
screening.
bRelative risk in FOBt-positive versus FOBt-negative women, adjusted for age, socioeconomic group, smoking status, alcohol intake and body mass index.
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5-fold risk of upper gastrointestinal cancer and 2-fold risk
of peptic ulcer or oesophagitis in the first 12 months after
screening (Figure 1B). It was also associated with a 3–5-
fold relative risk of anaemia or other bleeding tendency be-
ing diagnosed in the first 12 months after screening.
Women who attended the BCSP for diagnostic colonosco-
pies had higher relative risks for colorectal cancer and ade-
noma, although those who did not attend also had
considerably raised risks for both (Table 4). The RRs for co-
lorectal cancer in attenders and non-attenders were 220.5
(190.2 – 255.6) and 74.7 (52.8 – 105.6), respectively, and the
corresponding RRs for colorectal adenoma were 228.3
(208.3 – 250.2) and 21.1 (14.6 – 30.4), respectively;
P<0.0001 for all the RRs quoted. In validation analysis, the
RRs for colorectal cancer in attenders and non-attenders, us-
ing diagnoses ascertained from the cancer registry data, were
similar to those based on HES data, at 232.0 (201.1 – 269.9)
and 78.4 (55.8 – 110.1), respectively. The mean time between
FOBt screening invitation and HES record of colorectal can-
cer diagnosis was also similar in the 662 attenders and 38
non-attenders, at 3.0 [standard deviation (SD) 1.6] and 4.9
(SD 2.9) months, respectively. For upper gastrointestinal can-
cer and anaemia, RRs in the first 12 months after screening
were significantly greater in non-attenders than in attenders
for BCSP investigations.
In the 12–24 months after screening, the relative risks
for colorectal cancer (RR¼ 3.49, 2.31 – 5.26; P <0.0001)
and for colorectal adenoma (RR¼4.88, 3.80 – 6.26;
P <0.0001) remain elevated in in FOBt-positive versus
FOBT-negative women, although much lower than in the
preceding 12 months (for colorectal cancer, the numbers
were 24 and 475, respectively; and for colorectal adenoma,
the numbers were 66 and 1075, respectively). There was
also an increased risk of being diagnosed with other colo-
rectal, upper gastrointestinal and haematological condi-
tions (Figure 2). The RRs of being diagnosed with any of
the eight conditions other than colorectal neoplasms were
about doubled, both before screening and in the 12–
24 months after screening, at 1.81 (1.72 – 1.90) and 1.92
(1.70 – 2.17), respectively.
A
B
Figure 1 Risk ratios for various conditions first diagnosed in the 12 months after positive FOBt. [A] shows the risk ratios for colorectal conditions.
[B] shows the risk ratios for upper gastrointestinal and haematological conditions. Note different scales are used in (A) and (B) in the figure.
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Discussion
Many countries, such as the UK and Australia, have imple-
mented population-based screening programmes using
FOBt.13 However, conditions other than colorectal neo-
plasms can affect the test result, and the specificity of FOBt
has been found to be variable.14 This is the first study to
examine systematically, in a large cohort of 604 495
women who took part in routine bowel cancer screening in
England, associations between FOBt positivity and clinical
conditions related to gastrointestinal bleeding, both before
and after screening.
In this study, 1.5% of those screened were FOBt-
positive, and 7.9% of those who were FOBt-positive were
diagnosed with colorectal cancer in the first 12 months af-
ter screening. These findings are consistent with previous
estimates reported by the UK Bowel Cancer Screening
Programme.8,15,16 Compared with FOBt-negative women,
FOBt-positive women had a 200-fold greater risk of being
diagnosed with colorectal neoplasms in the first 12 months
after screening, falling to a 3–5-fold relative risk in the 12–
24 months after screening. The findings here relate to the
prevalent round of colorectal cancer screening and the pos-
itive predictive value of screening has been reported to be
reduced after the prevalent screen.17–20 The excess risk of
colorectal neoplasms and of other conditions in the first
12 months after FOBt positivity reflects, in large part, that
FOBt-positive individuals are offered further investigations
by the BCSP whereas FOBt-negative individuals are not.
Almost 30% of the FOBt-positive women in this study
had a hospital diagnosis of a non-neoplastic colorectal con-
dition (mainly diverticular disease or haemorrhoids) in the
12 months after FOBt. Virtually all the diagnoses were
made at around the time of colonoscopy, which is gener-
ally recorded as day case hospital admission. Our findings
are in line with results reported by other organised screen-
ing programmes, that 24–38% of FOBt-positive individu-
als have non-neoplastic colorectal conditions identified
during diagnostic colonoscopies.15,21,22 Although divertic-
ular disease has been reported to account for some 40% of
clinical lower gastrointestinal bleeding episodes,23 it is gen-
erally considered an incidental finding in colonoscopy for
investigation of positive FOBt.24
About 15% of FOBt-positive women had a hospital ad-
mission with benign causes of upper gastrointestinal bleed-
ing before screening and in 1% this was first diagnosed in
the 12 months after screening, consistent with previous
findings.25–28 The majority of these conditions were non-
malignant, mostly peptic ulcer disease. In contrast, the pro-
portion of FOBt-positive women diagnosed with upper
gastrointestinal cancer (although statistically significantly
higher than in FOBt-negative women) is exceedingly low,
present in only about 0.1% of FOBt-positive women be-
fore testing and a further 0.1% in the next 12 months.
Other limited evidence indicate that considerably fewer
than 1% of FOBt-positive colonoscopy-negative patients
have upper gastrointestinal cancer.28–30
Table 4. Conditions diagnosed in hospital admission records for the first time in the initial 12 months after routine FOB testing in
FOBt-positive women, by attendance at Bowel Cancer Screening Programme for further diagnostic tests
Diagnosis in HES FOBt-positive who attended BCSP
for further diagnostic tests (n¼7678)
FOBt-positive who did not attend BCSP
for further diagnostic tests (n¼1174)
% (n) Adjusted RRa (95% CI) % (n) Adjusted RRa (95% CI)
Colorectal neoplasms
Colorectal cancer 8.62% (662) 220.5 (190.2 – 255.6) 3.24% (38) 74.7 (52.8 – 105.6)
Colorectal adenoma 21.8% (1674) 228.3 (208.3 – 250.2) 2.56% (30) 21.1 (14.6 – 30.4)
Colorectal non-neoplasticb
Inflammatory bowel disease 0.84% (59) 25.7 (19.1 – 34.6) 0.98% (11) 28.8 (15.6 – 53.1)
Diverticular disease 23.9% (1671) 49.1 (46.2 – 52.1) 3.72% (42) 5.99 (4.42 – 8.13)
Haemorrhoids 8.31% (582) 31.7 (28.8 – 34.8) 2.66% (30) 9.45 (6.58 – 13.56)
Upper gastrointestinalb
Oesophagitis 0.93% (65) 1.49 (1.17 – 1.91) 1.42% (16) 2.25 (1.38 – 3.68)
Peptic ulcer 1.49% (104) 2.24 (1.84 – 2.72) 1.95% (22) 2.86 (1.88 – 4.35)
Upper gastrointestinal cancer 0.09% (6) 3.59 (1.58 – 8.16) 0.35% (4) 14.1 (5.21 – 38.4)
Haematologicalb
Anaemia 0.87% (61) 4.13 (3.19 – 5.36) 2.75% (31) 12.4 (8.7 – 17.8)
Potential bleeding tendency 1.40% (98) 2.97 (2.43 – 3.64) 2.75% (31) 5.59 (3.92 – 7.97)
Any of the above, except colorectal neoplasms 37.4% (2577) 24.2 (23.1 – 25.2) 12.6% (135) 5.48 (4.62 – 6.49)
aRelative risk in FOBt-positive versus FOBT-negative women, adjusted for age, socioeconomic group, smoking status, alcohol intake and body mass index.
bWomen who were diagnosed with colorectal cancer within 24 months after routine FOBt were excluded from analyses relating to diagnoses other than cancer.
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Figure 2. Risk ratios for colorectal, upper gastrointestinal and haematological conditions first diagnosed before FOBt and those first diagnosed 12–
24 months after positive FOBt. *First hospital admission 12–24 months after FOBt, adjusted for socioeconomic group, body mass index, alcohol con-
sumption and smoking status. ‘Colorectal neoplasms’ encompasses colorectal cancer and colorectal polyps.
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The relative risks of being diagnosed with anaemia
(>95% were iron deficiency anaemia) in FOBt-positive ver-
sus FOBt-negative women, before and after screening, range
from 3 to 5. The anaemia itself may not necessarily be
caused by gastrointestinal bleeding but could be a manifes-
tation of some other underlying haematological condition.
Approximately 6% of the FOBt-positive women had a pre-
vious hospital diagnosis of other specified haematological
conditions which could predispose to gastrointestinal bleed-
ing, and about 1.2% had a first diagnosis of one of these
conditions in the 12 months after FOB testing. The associ-
ated relative risks are approximately 3–4, suggesting that
the presence of these conditions influences FOBt positivity.
A small part of the excess risks for non-colorectal conditions
diagnosed after screening could be due to increased contact
with health professionals.
About one in eight who were FOBt-positive did not at-
tend further investigations organised by the BCSP. Non-
attenders were more likely than the attenders to have the
pre-existing conditions associated here with gastrointesti-
nal bleeding. Some have suggested that the most common
reasons for non-attendance at BCSP after FOBt positivity
include unwillingness to undergo a colonoscopy or inop-
portune timing,31 but our results suggest that many had
pre-existing conditions associated with gastrointestinal
bleeding and appeared to have diagnostic investigations
done elsewhere, possibly because they were already under
the care of other clinicians within the NHS.
The findings here are for a population-based NHS
screening programme using guaiac-based FOBt, and may
not be directly translatable to other screening programmes
that use immunochemical-based FOBt (faecal immuno-
chemical testing, FIT). The characteristics of screen-
detected and interval cancers are being reported
elsewhere.32
Some of the important strengths of this study include
having a virtually complete dataset on cause-specific NHS
hospital admissions, both before and after FOBt screening.
By linking BCSP data to information collected in the
Million Women Study, it was possible to obtain information
on clinical diagnoses recorded before screening as well as af-
ter screening, not only for the 87% of the FOBt-positive
women who attended the BCSP for further investigations,
but also for the 13% who did not. The main limitation of
this study is that diagnoses are restricted to those associated
with hospital admissions (overnight or day case stays) and
that it involved only women, who have lower rates of FOBt
positivity and lower risks of colorectal cancer and adenoma
compared with men. A systematic review has found the ac-
curacy of primary diagnosis codes in these hospital data to
be 96% after 2002.33 Some participants may have had out-
patient or primary care diagnoses for conditions such as
diverticular disease or haemorrhoids, which although ame-
nable to colonoscopic detection, could also have been diag-
nosed through radiological or clinical examinations.
Conclusion
Our study confirms that FOBt positivity in routine bowel
cancer screening is associated with a substantially in-
creased risk of colorectal neoplasms diagnosed in the first
12 months after screening, and a small excess risk in the
12–24 months after screening. It also showed that FOBt
positivity is associated with eight other gastrointestinal or
haematological conditions related to gastrointestinal bleed-
ing. These results emphasise the importance of reviewing
relevant medical history and discussion about other condi-
tions associated with gastrointestinal bleeding might be
considered when counselling patients with positive FOBt
results.
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